- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07682389
Etiologic Diagnosis Algorithm in Infective Endocarditis
28. juni 2026 opdateret af: I.M. Sechenov First Moscow State Medical University
Development and Validation of An Algorithm of Etiological Diagnosis of Infective Endocarditis in Adults: An Open-Label Multicenter Randomized Clinical Trial
The goal of this study is to evaluate the impact of a diagnostic algorithm combining culture-based and molecular methods on the frequency of etiotropic antibiotic therapy prescription within 14 days of diagnosis of infective endocarditis
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is an open-label (with blinded endpoint assessment) multicenter randomized trial designed to evaluate the impact of an etiological diagnostic algorithm incorporating various laboratory methods (culture-based and molecular) on the frequency of etiological antibiotic therapy prescription within 14 days after the diagnosis of infective endocarditis.
While molecular samples are collected from all participants, results are only disclosed to physicians in the intervention group to guide treatment, while remaining blinded in the control group.
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
128
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Svetlana Rachina, Professor
- Telefonnummer: +7 910 715-89-55
- E-mail: rachina_s_a@staff.sechenov.ru
Studiesteder
-
-
-
Moscow, Rusland
- Ikke rekrutterer endnu
- A.N. Bakulev National Medical Research Center for Cardiovascular Surgery of the Russian Ministry of Health
-
Kontakt:
- Dmitry Popov, Prof
-
Moscow, Rusland
- Rekruttering
- City Clinical Hospital Named After S. S. Yudin
-
Kontakt:
- Svetlana Rachina
- Telefonnummer: +7 910 715-89-55
- E-mail: rachina_s_a@staff.sechenov.ru
-
Moscow, Rusland
- Rekruttering
- City Clinical Hospital №67 Named After L. A. Vorokhobova
-
Kontakt:
- Svetlana Mirzakhamidova, Dr
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Informed consent,
- Age ≥ 18,
- IE (definite or possible per the 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis)
Exclusion Criteria:
- Pregnancy/breastfeeding
- Unconfirmed or rejected IE diagnosis,
- Very high risk of death within 14 days due to severe complications of the main or concomitant disease(s), according to the physician's opinion;
- Prior use of antibiotic therapy (except documented treatment failure).
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Comprehensive Etiological Diagnosis Group
Patients receive standard diagnostics plus molecular test results (PCR, PCR with sequencing) to guide etiotropic therapy
|
PCR and PCR with consequent sequencing of the blood (or tissue) will be performed in addition to the cultural methods in the experimental study arm
|
|
Aktiv komparator: Standard Clinical Practice Group
Patients receive standard care; molecular test results are blinded for the treating physician
|
Patients receive standard care with analysis of microorganisms in at least 2 or more separate blood culture sets and from cardiac tissue (if surgical treatment is performed); molecular test results are blinded for the treating physician
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of etiotropic antibiotic therapy prescription
Tidsramme: 14 days from the date of diagnosis
|
Proportion of patients receiving specific ABT within 14 days of diagnosis
|
14 days from the date of diagnosis
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
IE Complications requiring surgical treatment
Tidsramme: At discharge (an average of 14 days)
|
Proportion of patients with IE-related complications (uncontrolled infection, heart failure, or embolic events) requiring surgical treatment during hospitalization
|
At discharge (an average of 14 days)
|
|
Acute Kidney Injury
Tidsramme: At discharge (an average of 14 days)
|
Proportion of patients with acute kidney injury during hospitalization, defined as: increase in serum creatinine by ≥26.5 μmol/L within 48 hours, or increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days, or urine output <0.5 mL/kg/h for 6 hours. |
At discharge (an average of 14 days)
|
|
ICU Transfer
Tidsramme: At discharge (an average of 14 days)
|
Proportion of patients requiring transfer to the intensive care unit (ICU) during hospitalization (for admissions to non-ICU departments) or requiring repeated transfer to the ICU (if initially admitted to the ICU)
|
At discharge (an average of 14 days)
|
|
Mortality
Tidsramme: 30 days after diagnosis
|
Probability of death within 30 days after diagnosis, estimated using the Kaplan-Meier method
|
30 days after diagnosis
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
20. januar 2026
Primær færdiggørelse (Anslået)
4. februar 2027
Studieafslutning (Anslået)
20. februar 2027
Datoer for studieregistrering
Først indsendt
12. juni 2026
Først indsendt, der opfyldte QC-kriterier
28. juni 2026
Først opslået (Faktiske)
2. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
2. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
28. juni 2026
Sidst verificeret
1. april 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IE-2026
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
There is no current plan to share individual participant data (IPD) because data protection requirements and consent procedures for this study do not allow external data sharing beyond the study team.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Infektiøs endokarditis
-
Todd C. Lee MD MPH FIDSACanadian Institutes of Health Research (CIHR); McGill University Health... og andre samarbejdspartnereRekrutteringStaphylococcus Aureus Endocarditis | Prostetisk ventilendokarditisCanada
-
Montreal Heart InstituteRekrutteringInfektiøs endokarditis | Native Valve EndocarditisCanada
-
Region SkaneAfsluttet
-
University of PennsylvaniaTrukket tilbageStaphylococcus Aureus Bakteriæmi | Staphylococcus Aureus EndocarditisForenede Stater
-
ContraFectAfsluttetStaphylococcus Aureus Bakteriæmi | Staphylococcus Aureus EndocarditisForenede Stater, Belgien, Bulgarien, Chile, Tjekkiet, Frankrig, Tyskland, Grækenland, Guatemala, Israel, Italien, Den Russiske Føderation, Spanien, Det Forenede Kongerige
-
ContraFectAfsluttetStaphylococcus Aureus Bakteriæmi | Staphylococcus Aureus EndocarditisForenede Stater
-
Todd C. Lee MD MPH FIDSARekrutteringStaphylococcus Aureus Endocarditis | Staphylococcus Aureus Septikæmi | Staphylococcus Aureus blodbaneinfektionCanada
-
Todd C. Lee MD MPH FIDSARekrutteringStaphylococcus Aureus Bakteriæmi | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septikæmi | Staphylococcus sepsisCanada
-
Todd C. Lee MD MPH FIDSAUniversity of Melbourne; The Peter Doherty Institute for Infection and...RekrutteringDaptomycin vs. Vancomycin til behandling af methicillin-resistente S. Aureus-bakteriæmi (DAPTO-SNAP)Staphylococcus Aureus Bakteriæmi | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septikæmi | S. Aureus Bakteriæmi | S. Aureus BlodbaneinfektionAustralien, Canada
-
McGill University Health Centre/Research Institute...University of MelbourneRekrutteringStaphylococcus Aureus Bakteriæmi | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septikæmi | S. Aureus Bakteriæmi | S. Aureus Blodbaneinfektion | Staphylococcus Aureus blodbaneinfektionCanada
Kliniske forsøg med Molecular tests (PCR, sequencing)
-
Tianjin Medical University Second HospitalUkendt
-
University Hospital, AntwerpUniversitaire Ziekenhuizen KU Leuven; KU Leuven; Universiteit AntwerpenRekruttering
-
QuantuMDx Group LtdPathAI; Bright Research Center; New Day DiagnosticsAfsluttet
-
American Burn AssociationU.S. Army Medical Research and Development CommandAfsluttetSepsis | ForbrændingerForenede Stater
-
IgenomixUkendt
-
University Medical Centre LjubljanaAfsluttetLuftvejsvirusinfektioner | Multipel Mielom
-
The University of Hong KongIkke rekrutterer endnuCOVID-19 | Influenza | Akutte luftvejsinfektioner (ARI'er)Hong Kong
-
Centre Hospitalier Sud EssonneUkendt
-
Duke UniversityNorth Carolina Department of Health and Human ServicesAfsluttetCOVID-19Forenede Stater
-
Nanjing First Hospital, Nanjing Medical UniversityRekrutteringHelicobacter pylori infektionKina